{"protocolSection": {"identificationModule": {"nctId": "NCT01951625", "orgStudyIdInfo": {"id": "15371"}, "secondaryIdInfos": [{"id": "2013-002287-11", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bayer", "class": "INDUSTRY"}, "briefTitle": "Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)", "officialTitle": "A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)"}, "statusModule": {"statusVerifiedDate": "2021-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-11-29", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-05-14", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-09-24", "studyFirstSubmitQcDate": "2013-09-24", "studyFirstPostDateStruct": {"date": "2013-09-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-01-20", "resultsFirstSubmitQcDate": "2021-03-02", "resultsFirstPostDateStruct": {"date": "2021-03-25", "type": "ACTUAL"}, "dispFirstSubmitDate": "2015-08-28", "dispFirstSubmitQcDate": "2015-08-28", "dispFirstPostDateStruct": {"date": "2015-09-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-03-02", "lastUpdatePostDateStruct": {"date": "2021-03-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bayer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF)."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Worsening Heart Failure", "Heart Failure with Reduced Ejection Fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 456, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Vericiguat (BAY1021189) (10 mg)", "type": "EXPERIMENTAL", "description": "2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks", "interventionNames": ["Drug: Vericiguat (BAY1021189) (1.25 mg)", "Drug: Vericiguat (BAY1021189) (5 mg)"]}, {"label": "Vericiguat (BAY1021189) (5 mg)", "type": "EXPERIMENTAL", "description": "2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)", "interventionNames": ["Drug: Vericiguat (BAY1021189) (1.25 mg)", "Drug: Vericiguat (BAY1021189) (5 mg)"]}, {"label": "Vericiguat (BAY1021189) (2.5 mg)", "type": "EXPERIMENTAL", "description": "2.5 mg orally once daily for 12 weeks (with sham titrations)", "interventionNames": ["Drug: Vericiguat (BAY1021189) (1.25 mg)"]}, {"label": "Vericiguat (BAY1021189) (1.25 mg)", "type": "EXPERIMENTAL", "description": "1.25 mg orally once daily for 12 weeks (with sham titrations)", "interventionNames": ["Drug: Vericiguat (BAY1021189) (1.25 mg)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Orally once daily for 12 weeks (with sham titrations)", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Vericiguat (BAY1021189) (1.25 mg)", "description": "1.25 mg BAY1021189 tablets", "armGroupLabels": ["Vericiguat (BAY1021189) (1.25 mg)", "Vericiguat (BAY1021189) (10 mg)", "Vericiguat (BAY1021189) (2.5 mg)", "Vericiguat (BAY1021189) (5 mg)"]}, {"type": "DRUG", "name": "Vericiguat (BAY1021189) (5 mg)", "description": "5 mg BAY1021189 tablets", "armGroupLabels": ["Vericiguat (BAY1021189) (10 mg)", "Vericiguat (BAY1021189) (5 mg)"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12", "description": "Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is a circulating plasma biomarker of cardiovascular function and prognosis in heart failure.", "timeFrame": "Baseline, Week 12"}], "otherOutcomes": [{"measure": "Changes in Heart Function as Measured by Echocardiography, Left Ventricular End-Diastolic Volume (LVEDV), and Left Ventricular End-Systolic Volume (LVESV) From Baseline to Week 12", "description": "Left Ventricular End-Diastolic Volume (LVEDV) and Left ventricular end-systolic volume (LVESV) are measured echocardiography parameter. These are acquired during a non-invasive echocardiography examination.", "timeFrame": "Baseline, Week 12"}, {"measure": "Changes in Heart Function as Measured by Echocardiography, Left Ventricular Ejection Fraction (LVEF), From Baseline to Week 12", "description": "The left ventricular ejection fraction work index (LVEF) is a calculated echocardiography parameter. LVEF is derived from the directly measured parameters left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). These 2 parameters are acquired during a noninvasive echocardiography examination. Formula: LVEF = 100\\*(LVEDV - LVESV)/LVEDV.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in Systolic and Diastolic Blood Pressure to Week 12", "description": "Blood pressure was measured by monitor measurements after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart).The changes in blood pressure were recorded and the mean of the three measurements was analyzed.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in Heart Rate to Week 12", "description": "Heart rate was measured after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart). The changes in heart rate were recorded and the mean of the three measurements was analyzed.", "timeFrame": "Baseline, Week 12"}, {"measure": "Number of Subjects With Clinical Events (Heart Failure [HF] Hospitalization and Cardio-Vascular [CV] Mortality)", "description": "Clinical events (heart failure and mortality) were analyzed as CV death, and HF hospitalization at specified time points.", "timeFrame": "Baseline until 16 weeks"}, {"measure": "Number of Subjects With Implantable Cardioverter Defibrillators Cardiac Resynchronization Therapy With Defibrillation (ICD/CRT-D) Therapy", "description": "ICD / CRT with defibrillation therapy (CRT-D) included previous appropriate interventions such as shocks or anti-tachycardic pacing (ATP) when diagnostic of sustained ventricular tachycardias in pre defined rapid zone.", "timeFrame": "Baseline upto 16 weeks"}, {"measure": "Number of Subjects With Treatment-Emergent Adverse Events", "description": "An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; and another medically important serious event as judged by the investigator. AEs are considered to be treatment-emergent if they have started or worsened after first application of study drug up to 5 days after end of treatment with study drug.", "timeFrame": "From the start of study treatment upto 5 days after the last dose of study drug"}, {"measure": "Change in Biomarkers From Baseline to Week 12: Osteopontin (ng/mL)", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Biomarkers From Baseline to Week 12: TIMP-4 (pg/mL)", "description": "TIMP-4: tissue inhibitor of matrix metalloproteinases 4", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Biomarkers From Baseline to Week 12: cGMP (Pmol/mL)", "description": "cGMP: cyclic guanosine monophosphate", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Biomarkers From Baseline to Week 12: PIIINP (mcg/L)", "description": "PIIINP: pro-collagen III N-terminal peptide", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Biomarkers From Baseline to Week 12: GDF-15 (pg/mL)", "description": "GDF-15: growth differentiation factor 15", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Biomarkers From Baseline to Week 12: ST2 (pg/mL)", "description": "ST2: suppression of tumorigenicity 2", "timeFrame": "Baseline, Week 12"}, {"measure": "Change in Biomarkers From Baseline to Week 12: Gal-3 (\u03bcg/mL)", "description": "Gal-3: Galectin-3", "timeFrame": "Baseline, Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Worsening chronic heart failure (WCHF) requiring hospitalization (or intravenous diuretic treatment for HF without hospitalization) with initiation of study treatment after clinical stabilization\n* Left ventricular ejection fraction (LVEF) \\<45% by echocardiography at randomization\n\nExclusion Criteria:\n\n* Intravenous inotropes at any time after hospitalization", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bayer Study Director", "affiliation": "Bayer", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"city": "Wilmington", "state": "Delaware", "zip": "19803", "country": "United States", "geoPoint": {"lat": 39.74595, "lon": -75.54659}}, {"city": "Fort Lauderdale", "state": "Florida", "zip": "33308", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"city": "Jacksonville", "state": "Florida", "zip": "32209", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"city": "Naples", "state": "Florida", "zip": "34102", "country": "United States", "geoPoint": {"lat": 26.14234, "lon": -81.79596}}, {"city": "Atlanta", "state": "Georgia", "zip": "30342", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"city": "Macon", "state": "Georgia", "zip": "31201", "country": "United States", "geoPoint": {"lat": 32.84069, "lon": -83.6324}}, {"city": "New Orleans", "state": "Louisiana", "zip": "70112-1396", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"city": "Minneapolis", "state": "Minnesota", "zip": "55422", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"city": "Jackson", "state": "Mississippi", "zip": "39216-4505", "country": "United States", "geoPoint": {"lat": 32.29876, "lon": -90.18481}}, {"city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"city": "Fairfield", "state": "Ohio", "zip": "45014", "country": "United States", "geoPoint": {"lat": 39.34589, "lon": -84.5605}}, {"city": "Charleston", "state": "South Carolina", "zip": "29425", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"city": "Germantown", "state": "Tennessee", "zip": "38138", "country": "United States", "geoPoint": {"lat": 35.08676, "lon": -89.81009}}, {"city": "Nashville", "state": "Tennessee", "zip": "37232-8802", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"city": "Milwaukee", "state": "Wisconsin", "zip": "53215", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"city": "Darlinghurst", "state": "New South Wales", "zip": "2010", "country": "Australia", "geoPoint": {"lat": -33.87939, "lon": 151.21925}}, {"city": "Hobart", "state": "Tasmania", "zip": "7000", "country": "Australia", "geoPoint": {"lat": -42.87936, "lon": 147.32941}}, {"city": "Prahran", "state": "Victoria", "zip": "3181", "country": "Australia", "geoPoint": {"lat": -37.85114, "lon": 144.99318}}, {"city": "St. P\u00f6lten", "state": "Nieder\u00f6sterreich", "zip": "3100", "country": "Austria", "geoPoint": {"lat": 48.2, "lon": 15.63333}}, {"city": "Linz", "state": "Ober\u00f6sterreich", "zip": "4020", "country": "Austria", "geoPoint": {"lat": 48.30639, "lon": 14.28611}}, {"city": "Graz", "state": "Steiermark", "zip": "8036", "country": "Austria", "geoPoint": {"lat": 47.06667, "lon": 15.45}}, {"city": "Salzburg", "zip": "5020", "country": "Austria", "geoPoint": {"lat": 47.79941, "lon": 13.04399}}, {"city": "Wien", "zip": "1220", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"city": "Brugge", "zip": "8000", "country": "Belgium", "geoPoint": {"lat": 51.20892, "lon": 3.22424}}, {"city": "Bruxelles - Brussel", "zip": "1200", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"city": "Gilly", "zip": "6060", "country": "Belgium", "geoPoint": {"lat": 50.42449, "lon": 4.4789}}, {"city": "HUY", "zip": "4500", "country": "Belgium", "geoPoint": {"lat": 50.51894, "lon": 5.23284}}, {"city": "Mechelen", "zip": "2800", "country": "Belgium", "geoPoint": {"lat": 51.02574, "lon": 4.47762}}, {"city": "MOL", "zip": "2400", "country": "Belgium", "geoPoint": {"lat": 51.19188, "lon": 5.11662}}, {"city": "Roeselare", "zip": "8800", "country": "Belgium", "geoPoint": {"lat": 50.94653, "lon": 3.12269}}, {"city": "Sofia", "zip": "1202", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Sofia", "zip": "1233", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Sofia", "zip": "1309", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Sofia", "zip": "1527", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Stara Zagora", "zip": "6000", "country": "Bulgaria", "geoPoint": {"lat": 42.43278, "lon": 25.64194}}, {"city": "Toronto", "state": "Ontario", "zip": "M5B 1W8", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"city": "Montreal", "state": "Quebec", "zip": "H1T 1C8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"city": "Montreal", "state": "Quebec", "zip": "H2W 1T8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"city": "Saint-Jean-sur-Richelieu", "state": "Quebec", "zip": "J3A 1C3", "country": "Canada", "geoPoint": {"lat": 45.30713, "lon": -73.26259}}, {"city": "Sherbrooke", "state": "Quebec", "zip": "J1G 2E8", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"city": "Hradec kralove", "zip": "500 05", "country": "Czechia", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"city": "Kromeriz", "zip": "767 01", "country": "Czechia", "geoPoint": {"lat": 49.29785, "lon": 17.39312}}, {"facility": "Fakultni nemocnice Ostrava", "city": "Ostrava", "zip": "708 52", "country": "Czechia", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"city": "Praha 10", "zip": "10034", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Praha 2", "zip": "12808", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Praha 4", "zip": "140 21", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Praha 6", "zip": "169 02", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Slany", "zip": "274 01", "country": "Czechia", "geoPoint": {"lat": 50.23046, "lon": 14.08693}}, {"city": "Aalborg", "zip": "9000", "country": "Denmark", "geoPoint": {"lat": 57.048, "lon": 9.9187}}, {"city": "Aarhus N", "zip": "8200", "country": "Denmark", "geoPoint": {"lat": 56.15674, "lon": 10.21076}}, {"city": "Hellerup", "zip": "DK-2900", "country": "Denmark", "geoPoint": {"lat": 55.73204, "lon": 12.57093}}, {"city": "Viborg", "zip": "8800", "country": "Denmark", "geoPoint": {"lat": 56.45319, "lon": 9.40201}}, {"city": "BRON Cedex", "zip": "69677", "country": "France", "geoPoint": {"lat": 45.73333, "lon": 4.91667}}, {"city": "La Tronche", "zip": "38700", "country": "France", "geoPoint": {"lat": 45.20429, "lon": 5.73645}}, {"city": "Lille Cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"city": "Paris Cedex 15", "zip": "75908", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"city": "Pessac", "zip": "33604", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"city": "Rouen", "zip": "76031", "country": "France", "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"city": "M\u00fcnchen", "state": "Bayern", "zip": "80331", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"city": "Bad Homburg", "state": "Hessen", "zip": "61348", "country": "Germany", "geoPoint": {"lat": 50.22683, "lon": 8.61816}}, {"city": "Frankfurt", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"city": "Greifswald", "state": "Mecklenburg-Vorpommern", "zip": "17475", "country": "Germany", "geoPoint": {"lat": 54.09311, "lon": 13.38786}}, {"city": "Hannover", "state": "Niedersachsen", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"city": "K\u00f6ln", "state": "Nordrhein-Westfalen", "zip": "50924", "country": "Germany", "geoPoint": {"lat": 50.93333, "lon": 6.95}}, {"city": "M\u00fcnster", "state": "Nordrhein-Westfalen", "zip": "48149", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"city": "Homburg", "state": "Saarland", "zip": "66424", "country": "Germany", "geoPoint": {"lat": 49.32637, "lon": 7.33867}}, {"city": "Erfurt", "state": "Th\u00fcringen", "zip": "99089", "country": "Germany", "geoPoint": {"lat": 50.9787, "lon": 11.03283}}, {"city": "Hamburg", "zip": "20246", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"city": "Athens", "zip": "11527", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"city": "Nea Ionia", "zip": "14233", "country": "Greece", "geoPoint": {"lat": 38.0357, "lon": 23.75733}}, {"city": "Budapest", "zip": "1032", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"city": "Kistarcsa", "zip": "H-2143", "country": "Hungary", "geoPoint": {"lat": 47.54757, "lon": 19.26247}}, {"city": "Szekesfehervar", "zip": "8000", "country": "Hungary", "geoPoint": {"lat": 47.18995, "lon": 18.41034}}, {"city": "Afula", "zip": "1834111", "country": "Israel", "geoPoint": {"lat": 32.60907, "lon": 35.2892}}, {"city": "Ashkelon", "zip": "7830604", "country": "Israel", "geoPoint": {"lat": 31.66926, "lon": 34.57149}}, {"city": "Hadera", "zip": "3810101", "country": "Israel", "geoPoint": {"lat": 32.44192, "lon": 34.9039}}, {"city": "Jerusalem", "zip": "9103102", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"city": "Petah Tikva", "zip": "4941492", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"city": "Rehovot", "zip": "7610001", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"city": "Tel Aviv", "zip": "6423906", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"city": "Tiberias", "zip": "1528001", "country": "Israel", "geoPoint": {"lat": 32.79221, "lon": 35.53124}}, {"city": "Zrifin", "zip": "7030000", "country": "Israel", "geoPoint": {"lat": 31.95857, "lon": 4.83723}}, {"city": "Bergamo", "state": "Lombardia", "zip": "24127", "country": "Italy", "geoPoint": {"lat": 45.69601, "lon": 9.66721}}, {"city": "Brescia", "state": "Lombardia", "zip": "25123", "country": "Italy", "geoPoint": {"lat": 45.53558, "lon": 10.21472}}, {"city": "Como", "state": "Lombardia", "zip": "22020", "country": "Italy", "geoPoint": {"lat": 45.80819, "lon": 9.0832}}, {"city": "Milano", "state": "Lombardia", "zip": "20017", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"city": "Milano", "state": "Lombardia", "zip": "20138", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"city": "Milano", "state": "Lombardia", "zip": "20149", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"city": "Pavia", "state": "Lombardia", "zip": "27100", "country": "Italy", "geoPoint": {"lat": 45.19205, "lon": 9.15917}}, {"city": "Ancona", "state": "Marche", "zip": "60126", "country": "Italy", "geoPoint": {"lat": 43.5942, "lon": 13.50337}}, {"city": "Arezzo", "state": "Toscana", "zip": "52040", "country": "Italy", "geoPoint": {"lat": 43.46276, "lon": 11.88068}}, {"city": "Verona", "state": "Veneto", "zip": "37045", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"city": "Iizuka", "state": "Fukuoka", "zip": "820-8505", "country": "Japan", "geoPoint": {"lat": 33.63654, "lon": 130.68678}}, {"city": "Himeji", "state": "Hyogo", "zip": "670-0981", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"city": "Kanazawa", "state": "Ishikawa", "zip": "920-8650", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"city": "Sagamihara", "state": "Kanagawa", "zip": "252-5188", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"city": "Yokohama", "state": "Kanagawa", "zip": "236-0051", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"city": "Yokosuka", "state": "Kanagawa", "zip": "238-8567", "country": "Japan", "geoPoint": {"lat": 35.28361, "lon": 139.66722}}, {"city": "Sendai", "state": "Miyagi", "zip": "981-3133", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"city": "Naha", "state": "Okinawa", "zip": "902-8511", "country": "Japan", "geoPoint": {"lat": 26.21667, "lon": 127.68333}}, {"city": "Takatsuki", "state": "Osaka", "zip": "569-1096", "country": "Japan", "geoPoint": {"lat": 34.84833, "lon": 135.61678}}, {"city": "Yao", "state": "Osaka", "zip": "581-0011", "country": "Japan", "geoPoint": {"lat": 34.61667, "lon": 135.6}}, {"city": "Ureshino", "state": "Saga", "zip": "843-0393", "country": "Japan"}, {"city": "Komatsushima", "state": "Tokushima", "zip": "773-8502", "country": "Japan"}, {"city": "Meguro-ku", "state": "Tokyo", "zip": "152-8902", "country": "Japan", "geoPoint": {"lat": 42.12755, "lon": 143.31736}}, {"city": "Minato-ku", "state": "Tokyo", "zip": "106-0031", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"city": "Fukui", "zip": "910-8526", "country": "Japan", "geoPoint": {"lat": 36.06443, "lon": 136.22257}}, {"city": "Hiroshima", "zip": "734-8530", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"city": "Kumamoto", "zip": "862-8505", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"city": "Nagasaki", "zip": "850-8555", "country": "Japan", "geoPoint": {"lat": 32.75, "lon": 129.88333}}, {"city": "Tokushima", "zip": "770-8539", "country": "Japan", "geoPoint": {"lat": 34.06667, "lon": 134.56667}}, {"city": "Toyama", "zip": "930-8550", "country": "Japan", "geoPoint": {"lat": 36.7, "lon": 137.21667}}, {"city": "Seoul", "zip": "138-736", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"city": "Amsterdam", "zip": "1105 AZ", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}, {"city": "Deventer", "zip": "7416 SE", "country": "Netherlands", "geoPoint": {"lat": 52.255, "lon": 6.16389}}, {"city": "Heerenveen", "zip": "8441 PW", "country": "Netherlands", "geoPoint": {"lat": 52.95929, "lon": 5.91854}}, {"city": "Leeuwarden", "zip": "8901 BR", "country": "Netherlands", "geoPoint": {"lat": 53.20139, "lon": 5.80859}}, {"city": "Veldhoven", "zip": "5504 DB", "country": "Netherlands", "geoPoint": {"lat": 51.41833, "lon": 5.40278}}, {"city": "Bialystok", "zip": "15-276", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"city": "Krakow", "zip": "31-202", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"city": "Legnica", "zip": "59-220", "country": "Poland", "geoPoint": {"lat": 51.21006, "lon": 16.1619}}, {"city": "Lodz", "zip": "92-213", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"city": "Olsztyn", "zip": "10-010", "country": "Poland", "geoPoint": {"lat": 53.77995, "lon": 20.49416}}, {"city": "Poznan", "zip": "61-848", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"city": "Warszawa", "zip": "02-507", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"city": "Singapore", "zip": "119228", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"city": "Singapore", "zip": "169609", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"city": "Singapore", "zip": "308433", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"city": "Singapore", "zip": "768828", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"city": "L'Hospitalet de Llobregat", "state": "Barcelona", "zip": "08907", "country": "Spain", "geoPoint": {"lat": 41.35967, "lon": 2.10028}}, {"city": "Santander", "state": "Cantabria", "zip": "39008", "country": "Spain", "geoPoint": {"lat": 43.46472, "lon": -3.80444}}, {"city": "Majadahonda", "state": "Madrid", "zip": "28222", "country": "Spain", "geoPoint": {"lat": 40.47353, "lon": -3.87182}}, {"city": "Barcelona", "zip": "08003", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"city": "Barcelona", "zip": "08023", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"city": "Valencia", "zip": "46010", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"city": "Valencia", "zip": "46026", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"city": "Helsingborg", "zip": "251 87", "country": "Sweden", "geoPoint": {"lat": 56.04673, "lon": 12.69437}}, {"city": "Karlstad", "zip": "651 85", "country": "Sweden", "geoPoint": {"lat": 59.3793, "lon": 13.50357}}, {"city": "Link\u00f6ping", "zip": "581 85", "country": "Sweden", "geoPoint": {"lat": 58.41086, "lon": 15.62157}}, {"city": "Malm\u00f6", "zip": "205 02", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"city": "Stockholm", "zip": "118 83", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"city": "\u00d6rebro", "zip": "701 85", "country": "Sweden", "geoPoint": {"lat": 59.27412, "lon": 15.2066}}, {"city": "Liestal", "state": "Basel-Landschaft", "zip": "4410", "country": "Switzerland", "geoPoint": {"lat": 47.48455, "lon": 7.73446}}, {"city": "Bruderholz", "zip": "4101", "country": "Switzerland", "geoPoint": {"lat": 47.5296, "lon": 7.59902}}, {"city": "Lugano", "zip": "6900", "country": "Switzerland", "geoPoint": {"lat": 46.01008, "lon": 8.96004}}, {"city": "Z\u00fcrich", "zip": "8091", "country": "Switzerland", "geoPoint": {"lat": 47.36667, "lon": 8.54999}}, {"city": "Kaohsiung", "zip": "813", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"city": "New Taipei City", "zip": "220", "country": "Taiwan", "geoPoint": {"lat": 25.01111, "lon": 121.44583}}, {"city": "Taipei", "zip": "10016", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"city": "Taipei", "zip": "11217", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"city": "Chesterfield", "state": "Derbyshire", "zip": "S44 5DX", "country": "United Kingdom", "geoPoint": {"lat": 53.25, "lon": -1.41667}}, {"city": "Stevenage", "state": "Hertfordshire", "zip": "SG1 4AB", "country": "United Kingdom", "geoPoint": {"lat": 51.90224, "lon": -0.20256}}]}, "referencesModule": {"references": [{"pmid": "25056511", "type": "RESULT", "citation": "Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Muller K, Roessig L, Gheorghiade M; SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026-38. doi: 10.1002/ejhf.135. Epub 2014 Jul 24."}, {"pmid": "26547357", "type": "RESULT", "citation": "Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Muller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734."}, {"pmid": "34086190", "type": "DERIVED", "citation": "Ruehs H, Klein D, Frei M, Grevel J, Austin R, Becker C, Roessig L, Pieske B, Garmann D, Meyer M. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Clin Pharmacokinet. 2021 Nov;60(11):1407-1421. doi: 10.1007/s40262-021-01024-y. Epub 2021 Jun 4."}, {"pmid": "32216011", "type": "DERIVED", "citation": "Kramer F, Voss S, Roessig L, Igl BW, Butler J, Lam CSP, Maggioni AP, Shah SJ, Pieske B. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020 Sep;22(9):1675-1683. doi: 10.1002/ejhf.1787. Epub 2020 Mar 25."}], "seeAlsoLinks": [{"label": "Click here to find results for studies related to Bayer Healthcare products.", "url": "https://clinicaltrials.bayer.com/"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Overall 632 subjects were enrolled, of them 176 were screen failure and 456 were randomized. One subject did not receive study drug after randomization. Among the 455 subjects who received study drug 348 completed the study (that is completed both the treatment and follow-up periods) and 108 subjects did not complete the study.", "recruitmentDetails": "The study was conducted at 144 centers in 24 countries between 29 November 2013 (first subject first visit) and 09 June 2015 (last subject last visit).", "groups": [{"id": "FG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "FG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "FG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "FG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "FG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "periods": [{"title": "Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "91"}, {"groupId": "FG002", "numSubjects": "91"}, {"groupId": "FG003", "numSubjects": "91"}, {"groupId": "FG004", "numSubjects": "91"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "73"}, {"groupId": "FG001", "numSubjects": "70"}, {"groupId": "FG002", "numSubjects": "76"}, {"groupId": "FG003", "numSubjects": "69"}, {"groupId": "FG004", "numSubjects": "74"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "22"}, {"groupId": "FG004", "numSubjects": "17"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Protocol driven decision point", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Non compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "8"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Follow Up Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "87"}, {"groupId": "FG001", "numSubjects": "88"}, {"groupId": "FG002", "numSubjects": "88"}, {"groupId": "FG003", "numSubjects": "87"}, {"groupId": "FG004", "numSubjects": "88"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "79"}, {"groupId": "FG001", "numSubjects": "79"}, {"groupId": "FG002", "numSubjects": "84"}, {"groupId": "FG003", "numSubjects": "76"}, {"groupId": "FG004", "numSubjects": "78"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "11"}, {"groupId": "FG004", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Logistical difficulties", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "BG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "BG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "BG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "BG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "91"}, {"groupId": "BG002", "value": "91"}, {"groupId": "BG003", "value": "91"}, {"groupId": "BG004", "value": "91"}, {"groupId": "BG005", "value": "456"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67", "spread": "13.1"}, {"groupId": "BG001", "value": "67.6", "spread": "12.9"}, {"groupId": "BG002", "value": "67.6", "spread": "11.5"}, {"groupId": "BG003", "value": "66.7", "spread": "11.6"}, {"groupId": "BG004", "value": "68.9", "spread": "12.4"}, {"groupId": "BG005", "value": "67.6", "spread": "12.3"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<65", "measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "30"}, {"groupId": "BG003", "value": "38"}, {"groupId": "BG004", "value": "28"}, {"groupId": "BG005", "value": "172"}]}, {"title": "65-75", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "32"}, {"groupId": "BG004", "value": "34"}, {"groupId": "BG005", "value": "148"}]}, {"title": "> 75", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "21"}, {"groupId": "BG004", "value": "29"}, {"groupId": "BG005", "value": "136"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "17"}, {"groupId": "BG004", "value": "14"}, {"groupId": "BG005", "value": "90"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "72"}, {"groupId": "BG003", "value": "74"}, {"groupId": "BG004", "value": "77"}, {"groupId": "BG005", "value": "366"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12", "description": "Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is a circulating plasma biomarker of cardiovascular function and prognosis in heart failure.", "populationDescription": "Per Protocol Set (PPS)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "log-transformed picograms per milliliter", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}, {"id": "OG005", "title": "Pooled 2.5 mg up to 10 mg", "description": "The three highest dose arms (BAY1021189 2.5 mg, 2.5-5 mg, and 2.5-10 mg) were pooled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "67"}, {"groupId": "OG004", "value": "73"}, {"groupId": "OG005", "value": "213"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.28", "spread": "0.8197"}, {"groupId": "OG001", "value": "-0.265", "spread": "0.7658"}, {"groupId": "OG002", "value": "-0.32", "spread": "0.7799"}, {"groupId": "OG003", "value": "-0.353", "spread": "0.8404"}, {"groupId": "OG004", "value": "-0.529", "spread": "0.9475"}, {"groupId": "OG005", "value": "-0.402", "spread": "0.8603"}]}]}], "analyses": [{"groupIds": ["OG000", "OG005"], "groupDescription": "For the primary analysis, the three highest active treatment groups (BAY1021189 2.5mg, BAY1021189 2.5 to 5mg, BAY1021189 2.5 to 10mg) were pooled and compared to the assigned placebo treatment group with a one-sided two-sample t-test at the significance level of 5 percent (%). Results are reported including 90% confidence intervals (CI) for the difference of means. The difference between the pooled treatment group and the placebo group is difference of means on the log scale.", "nonInferiorityType": "OTHER", "pValue": "= 0.1506", "statisticalMethod": "t-test, 1 sided", "paramType": "Log-Scale mean difference", "paramValue": "-0.122", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.32", "ciUpperLimit": "0.07"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "In case of a significant result in the primary analysis of the primary endpoint, pairwise comparisons to Placebo were performed in a hierarchical manner (from BAY1021189 from 2.5 to 10mg dose arm to BAY1021189 1.25mg dose arm). In case of non-significance of the primary analyses, these secondary analyses were specified as exploratory only, since the primary analyses were not significant.", "nonInferiorityType": "OTHER", "pValue": "= 0.0483", "statisticalMethod": "t-test, 1 sided", "paramType": "Log-Scale mean difference", "paramValue": "-0.2494", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.5", "ciUpperLimit": "0"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "In case of a significant result in the primary analysis of the primary endpoint, pairwise comparisons to Placebo were performed in a hierarchical manner (from BAY1021189 from 2.5 to 10mg dose arm to BAY1021189 1.25mg dose arm). In case of non-significance of the primary analyses, these secondary analyses were specified as exploratory only, since the primary analyses were not significant.", "nonInferiorityType": "OTHER", "pValue": "= 0.3042", "statisticalMethod": "t-test, 1 sided", "paramType": "Log-Scale mean difference", "paramValue": "-0.0731", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.31", "ciUpperLimit": "0.16"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "In case of a significant result in the primary analysis of the primary endpoint, pairwise comparisons to Placebo were performed in a hierarchical manner (from BAY1021189 from 2.5 to 10mg dose arm to BAY1021189 1.25mg dose arm). In case of non-significance of the primary analyses, these secondary analyses were specified as exploratory only, since the primary analyses were not significant.", "nonInferiorityType": "OTHER", "pValue": "= 0.3841", "statisticalMethod": "t-test, 1 sided", "paramType": "Log-Scale mean difference", "paramValue": "-0.0396", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.26", "ciUpperLimit": "0.18"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "In case of a significant result in the primary analysis of the primary endpoint, pairwise comparisons to Placebo were performed in a hierarchical manner (from BAY1021189 from 2.5 to 10mg dose arm to BAY1021189 1.25mg dose arm). In case of non-significance of the primary analyses, these secondary analyses were specified as exploratory only.", "nonInferiorityType": "OTHER", "pValue": "= 0.5444", "statisticalMethod": "t-test, 1 sided", "paramType": "Log-Scale mean difference", "paramValue": "0.0151", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.21", "ciUpperLimit": "0.24"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Changes in Heart Function as Measured by Echocardiography, Left Ventricular End-Diastolic Volume (LVEDV), and Left Ventricular End-Systolic Volume (LVESV) From Baseline to Week 12", "description": "Left Ventricular End-Diastolic Volume (LVEDV) and Left ventricular end-systolic volume (LVESV) are measured echocardiography parameter. These are acquired during a non-invasive echocardiography examination.", "populationDescription": "Evaluable subjects in full analysis set (FAS).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "milliliter", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "91"}, {"groupId": "OG003", "value": "91"}, {"groupId": "OG004", "value": "91"}]}], "classes": [{"title": "Change in LVEDV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "69"}, {"groupId": "OG003", "value": "63"}, {"groupId": "OG004", "value": "70"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.259", "spread": "40.676"}, {"groupId": "OG001", "value": "-5.525", "spread": "34.75"}, {"groupId": "OG002", "value": "-9.632", "spread": "35.081"}, {"groupId": "OG003", "value": "-17.093", "spread": "53.307"}, {"groupId": "OG004", "value": "-7.324", "spread": "31.896"}]}]}, {"title": "Change in LVESV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "69"}, {"groupId": "OG003", "value": "63"}, {"groupId": "OG004", "value": "71"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.83", "spread": "32.407"}, {"groupId": "OG001", "value": "-8.585", "spread": "27.385"}, {"groupId": "OG002", "value": "-10.935", "spread": "27.146"}, {"groupId": "OG003", "value": "-15.485", "spread": "43.191"}, {"groupId": "OG004", "value": "-11.017", "spread": "26.525"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Changes in Heart Function as Measured by Echocardiography, Left Ventricular Ejection Fraction (LVEF), From Baseline to Week 12", "description": "The left ventricular ejection fraction work index (LVEF) is a calculated echocardiography parameter. LVEF is derived from the directly measured parameters left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). These 2 parameters are acquired during a noninvasive echocardiography examination. Formula: LVEF = 100\\*(LVEDV - LVESV)/LVEDV.", "populationDescription": "Evaluable subjects in full analysis set (FAS).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "91"}, {"groupId": "OG003", "value": "91"}, {"groupId": "OG004", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.515", "spread": "4.736"}, {"groupId": "OG001", "value": "2.84", "spread": "3.635"}, {"groupId": "OG002", "value": "2.741", "spread": "4.371"}, {"groupId": "OG003", "value": "2.07", "spread": "4.808"}, {"groupId": "OG004", "value": "3.682", "spread": "6.19"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Systolic and Diastolic Blood Pressure to Week 12", "description": "Blood pressure was measured by monitor measurements after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart).The changes in blood pressure were recorded and the mean of the three measurements was analyzed.", "populationDescription": "Evaluable subjects in safety analysis set (SAF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeter of mercury (mmHg)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "90"}, {"groupId": "OG003", "value": "91"}, {"groupId": "OG004", "value": "91"}]}], "classes": [{"title": "Change in SBP", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "75"}, {"groupId": "OG003", "value": "69"}, {"groupId": "OG004", "value": "74"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.142", "spread": "12.829"}, {"groupId": "OG001", "value": "-4.033", "spread": "13.3"}, {"groupId": "OG002", "value": "-3.733", "spread": "16.509"}, {"groupId": "OG003", "value": "-3.043", "spread": "15.934"}, {"groupId": "OG004", "value": "-5.64", "spread": "15.509"}]}]}, {"title": "Change in DBP", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "75"}, {"groupId": "OG003", "value": "69"}, {"groupId": "OG004", "value": "74"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.173", "spread": "8.6"}, {"groupId": "OG001", "value": "-0.486", "spread": "9.298"}, {"groupId": "OG002", "value": "-2.938", "spread": "11.101"}, {"groupId": "OG003", "value": "-1.338", "spread": "9.528"}, {"groupId": "OG004", "value": "-4.045", "spread": "10.604"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Heart Rate to Week 12", "description": "Heart rate was measured after 10 minutes resting in a supine position (3 measurements taken approximately 2 minutes apart). The changes in heart rate were recorded and the mean of the three measurements was analyzed.", "populationDescription": "Evaluable subjects in safety analysis set (SAF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per minute", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "90"}, {"groupId": "OG003", "value": "91"}, {"groupId": "OG004", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.562", "spread": "12.897"}, {"groupId": "OG001", "value": "-0.352", "spread": "10.153"}, {"groupId": "OG002", "value": "-1.556", "spread": "10.2"}, {"groupId": "OG003", "value": "-0.99", "spread": "11.295"}, {"groupId": "OG004", "value": "0.545", "spread": "10.636"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Subjects With Clinical Events (Heart Failure [HF] Hospitalization and Cardio-Vascular [CV] Mortality)", "description": "Clinical events (heart failure and mortality) were analyzed as CV death, and HF hospitalization at specified time points.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline until 16 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "91"}, {"groupId": "OG003", "value": "91"}, {"groupId": "OG004", "value": "91"}]}], "classes": [{"title": "HF hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "20"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "9"}]}]}, {"title": "CV death", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Subjects With Implantable Cardioverter Defibrillators Cardiac Resynchronization Therapy With Defibrillation (ICD/CRT-D) Therapy", "description": "ICD / CRT with defibrillation therapy (CRT-D) included previous appropriate interventions such as shocks or anti-tachycardic pacing (ATP) when diagnostic of sustained ventricular tachycardias in pre defined rapid zone.", "populationDescription": "No analysis was performed for this end point.", "reportingStatus": "POSTED", "timeFrame": "Baseline upto 16 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Subjects With Treatment-Emergent Adverse Events", "description": "An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; and another medically important serious event as judged by the investigator. AEs are considered to be treatment-emergent if they have started or worsened after first application of study drug up to 5 days after end of treatment with study drug.", "populationDescription": "SAF", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the start of study treatment upto 5 days after the last dose of study drug", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "91"}, {"groupId": "OG002", "value": "90"}, {"groupId": "OG003", "value": "91"}, {"groupId": "OG004", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "62"}, {"groupId": "OG004", "value": "56"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Biomarkers From Baseline to Week 12: Osteopontin (ng/mL)", "populationDescription": "Evaluable subjects in FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nanogram(s)/milliliter (ng/mL)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "65"}, {"groupId": "OG004", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.79", "spread": "42.049", "lowerLimit": "42.049"}, {"groupId": "OG001", "value": "3.812", "spread": "39.248", "lowerLimit": "39.248"}, {"groupId": "OG002", "value": "3.266", "spread": "52.957", "lowerLimit": "52.957"}, {"groupId": "OG003", "value": "8.485", "spread": "41.97", "lowerLimit": "41.97"}, {"groupId": "OG004", "value": "3.709", "spread": "36.048", "lowerLimit": "36.048"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Biomarkers From Baseline to Week 12: TIMP-4 (pg/mL)", "description": "TIMP-4: tissue inhibitor of matrix metalloproteinases 4", "populationDescription": "Evaluable subjects in FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "picogram(s)/millilitre (pg/mL)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "72"}, {"groupId": "OG003", "value": "67"}, {"groupId": "OG004", "value": "72"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "451.889", "spread": "1392.03", "lowerLimit": "1392.03"}, {"groupId": "OG001", "value": "1128.635", "spread": "1949.351", "lowerLimit": "1949.351"}, {"groupId": "OG002", "value": "643.626", "spread": "1441.954", "lowerLimit": "1441.954"}, {"groupId": "OG003", "value": "876.584", "spread": "1559.768", "lowerLimit": "1559.768"}, {"groupId": "OG004", "value": "397.603", "spread": "1420.223", "lowerLimit": "1420.223"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Biomarkers From Baseline to Week 12: cGMP (Pmol/mL)", "description": "cGMP: cyclic guanosine monophosphate", "populationDescription": "Evaluable subjects in FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "picomole(s)/milliliter (pmol/mL)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "66"}, {"groupId": "OG004", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "78.874", "spread": "143.321", "lowerLimit": "143.321"}, {"groupId": "OG001", "value": "79.767", "spread": "123.031", "lowerLimit": "123.031"}, {"groupId": "OG002", "value": "92.352", "spread": "121.477", "lowerLimit": "121.477"}, {"groupId": "OG003", "value": "80.888", "spread": "114.09", "lowerLimit": "114.09"}, {"groupId": "OG004", "value": "63.563", "spread": "127.448", "lowerLimit": "127.448"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Biomarkers From Baseline to Week 12: PIIINP (mcg/L)", "description": "PIIINP: pro-collagen III N-terminal peptide", "populationDescription": "Evaluable subjects in FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "microgram(s)/liter (mcg/L)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "72"}, {"groupId": "OG003", "value": "67"}, {"groupId": "OG004", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.701", "spread": "7.246", "lowerLimit": "7.246"}, {"groupId": "OG001", "value": "0.092", "spread": "3.958", "lowerLimit": "3.958"}, {"groupId": "OG002", "value": "0.106", "spread": "5.145", "lowerLimit": "5.145"}, {"groupId": "OG003", "value": "-0.71", "spread": "3.774", "lowerLimit": "3.774"}, {"groupId": "OG004", "value": "-0.321", "spread": "4.452", "lowerLimit": "4.452"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Biomarkers From Baseline to Week 12: GDF-15 (pg/mL)", "description": "GDF-15: growth differentiation factor 15", "populationDescription": "Evaluable subjects in FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "66"}, {"groupId": "OG004", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "429.432", "spread": "3212.229", "lowerLimit": "3212.229"}, {"groupId": "OG001", "value": "496.456", "spread": "3132.738", "lowerLimit": "3132.738"}, {"groupId": "OG002", "value": "285.472", "spread": "2837.237", "lowerLimit": "2837.237"}, {"groupId": "OG003", "value": "468.369", "spread": "1786.062", "lowerLimit": "1786.062"}, {"groupId": "OG004", "value": "244.63", "spread": "2906.763", "lowerLimit": "2906.763"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Biomarkers From Baseline to Week 12: ST2 (pg/mL)", "description": "ST2: suppression of tumorigenicity 2", "populationDescription": "Evaluable subjects in FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "72"}, {"groupId": "OG003", "value": "67"}, {"groupId": "OG004", "value": "72"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9457.677", "spread": "54702.45", "lowerLimit": "54702.45"}, {"groupId": "OG001", "value": "1623.869", "spread": "25086.72", "lowerLimit": "25086.72"}, {"groupId": "OG002", "value": "-1217.77", "spread": "35166.41", "lowerLimit": "35166.41"}, {"groupId": "OG003", "value": "6933.941", "spread": "20747.71", "lowerLimit": "20747.71"}, {"groupId": "OG004", "value": "3681.668", "spread": "32293.77", "lowerLimit": "32293.77"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Biomarkers From Baseline to Week 12: Gal-3 (\u03bcg/mL)", "description": "Gal-3: Galectin-3", "populationDescription": "Evaluable subjects in FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mcg/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28."}, {"id": "OG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28."}, {"id": "OG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "64"}, {"groupId": "OG004", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.802", "spread": "13.818", "lowerLimit": "13.818"}, {"groupId": "OG001", "value": "0.233", "spread": "6.208", "lowerLimit": "6.208"}, {"groupId": "OG002", "value": "-0.287", "spread": "3.729", "lowerLimit": "3.729"}, {"groupId": "OG003", "value": "0.064", "spread": "5.64", "lowerLimit": "5.64"}, {"groupId": "OG004", "value": "-0.38", "spread": "4.551", "lowerLimit": "4.551"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Treatment-emergent AEs were collected after first application of study medication up to 5 calendar days after end of treatment with study medication.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Subjects received placebo matched to vericiguat (Verquvo, BAY1021189) orally once daily for 12 weeks. Sham titrations included on Days 14 and 28.", "deathsNumAffected": 6, "deathsNumAtRisk": 92, "seriousNumAffected": 30, "seriousNumAtRisk": 92, "otherNumAffected": 24, "otherNumAtRisk": 92}, {"id": "EG001", "title": "BAY1021189 1.25 Milligram (mg)", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 1.25 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28.", "deathsNumAffected": 6, "deathsNumAtRisk": 91, "seriousNumAffected": 26, "seriousNumAtRisk": 91, "otherNumAffected": 25, "otherNumAtRisk": 91}, {"id": "EG002", "title": "BAY1021189 2.5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) 2.5 mg orally once daily for 12 weeks. Sham titrations included on Days 14 and 28.", "deathsNumAffected": 5, "deathsNumAtRisk": 90, "seriousNumAffected": 26, "seriousNumAtRisk": 90, "otherNumAffected": 20, "otherNumAtRisk": 90}, {"id": "EG003", "title": "BAY1021189 From 2.5 to 5 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 or 28 days. Sham titration included on Day 28.", "deathsNumAffected": 3, "deathsNumAtRisk": 91, "seriousNumAffected": 20, "seriousNumAtRisk": 91, "otherNumAffected": 23, "otherNumAtRisk": 91}, {"id": "EG004", "title": "BAY1021189 From 2.5 to 10 mg", "description": "Subjects received vericiguat (Verquvo, BAY1021189) for 12 weeks, starting on 2.5 mg once daily with potential up-titration to 5 mg once daily after 14 days, and up-titration to 10 mg once daily after 28 days.", "deathsNumAffected": 4, "deathsNumAtRisk": 91, "seriousNumAffected": 25, "seriousNumAtRisk": 91, "otherNumAffected": 28, "otherNumAtRisk": 91}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 8, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 11, "numAffected": 10, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 4, "numAffected": 3, "numAtRisk": 91}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 6, "numAffected": 3, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 91}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 4, "numAffected": 3, "numAtRisk": 91}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Ischaemic cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Left ventricular dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Acute left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Mechanical ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Incarcerated umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Multi-organ failure", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "General physical health deterioration", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Device dislocation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Cholangitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}]}, {"term": "Escherichia sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Pneumococcal sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Incision site haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 2, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Fluid overload", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Transplant evaluation", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Metabolic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Intra-abdominal haemangioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Non-small cell lung cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Cervicobrachial syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 91}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Pulmonary congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Rash pruritic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Catheter placement", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}], "otherEvents": [{"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 7, "numAffected": 5, "numAtRisk": 91}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 91}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 6, "numAffected": 5, "numAtRisk": 91}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 5, "numAffected": 5, "numAtRisk": 91}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 91}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 91}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 92}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 91}, {"groupId": "EG004", "numEvents": 17, "numAffected": 14, "numAtRisk": 91}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Endpoints of \"Change in 'health-related quality of life', 'Composite Congestion Score', 'NYHA function class', and 'background heart failure therapies' were assessed as exploratory. \"Incidence of atrial fibrillation\" is reported in AE summary."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Therapeutic Area Head", "organization": "Bayer AG", "email": "clinical-trials-contact@bayer.com", "phone": "(+) 1-888-8422937"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China", "Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}